Sonnet BioTherapeutics Advances in SON-1010 Phase 1 Trial

Sonnet BioTherapeutics Holdings ( (SONN) ) has provided an update.

Sonnet BioTherapeutics has achieved a significant milestone in its Phase 1 SB101 trial for SON-1010, a targeted immunotherapeutic drug, by establishing a maximum tolerated dose of 1200 ng/kg without dose-limiting toxicity. The trial results indicate a promising 48% stability in disease among patients, with one experiencing a notable 45% tumor reduction. These findings highlight the potential of SON-1010 in treating advanced solid tumors, sparking interest for further development and partnerships.

For a thorough assessment of SONN stock, go to TipRanks’ Stock Analysis page.